S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Compare Stocks

Date Range: 

 PfizerEli Lilly andNovo Nordisk A/SAbbott LaboratoriesMerck & Co., Inc.
SymbolNYSE:PFENYSE:LLYNYSE:NVONYSE:ABTNYSE:MRK
Price Information
Current Price$51.48$246.33$107.75$132.47$73.42
50-Day Moving Average$46.45$248.37$106.49$124.21$81.01
52-Week Low$33.36$146.48$66.59$105.32$70.89
52-Week High$55.70$275.87$115.95$133.28$91.40
MarketRank™
Overall Score3.13.02.22.83.5
Analysis Score2.23.54.22.44.3
Community Score4.84.84.04.84.5
Dividend Score4.23.31.74.24.2
Ownership Score2.52.50.02.52.5
Earnings & Valuation Score1.90.61.30.01.9
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$50.53$272.71$592.00$136.57$95.27
% Upside from Price Target-1.84% downside10.71% upside449.42% upside3.10% upside29.76% upside
Trade Information
Market Cap$288.95 billion$235.64 billion$253.73 billion$234.24 billion$185.45 billion
Beta0.680.350.440.70.48
Average Volume31,733,3053,366,276962,4105,356,44212,673,553
Sales & Book Value
Annual Revenue$41.91 billion$24.54 billion$19.45 billion$34.61 billion$47.99 billion
Price / Sales6.899.6013.056.773.86
Cashflow$3.02 per share$8.89 per share$3.15 per share$5.75 per share$7.35 per share
Price / Cash17.0627.7034.2323.039.99
Book Value$13.53 per share$8.31 per share$4.45 per share$19.59 per share$14.20 per share
Price / Book3.8029.6424.216.765.17
Profitability
Net Income$9.62 billion$6.19 billion$6.46 billion$4.50 billion$7.07 billion
EPS$3.36$6.56$3.21$4.03$2.83
Trailing P/E Ratio15.3237.5533.5732.8725.94
Forward P/E Ratio11.2230.1929.8528.3110.69
P/E Growth1.231.952.702.121.92
Net Margins27.66%21.52%34.33%17.12%14.64%
Return on Equity (ROE)30.70%111.51%73.70%28.39%48.21%
Return on Assets (ROA)12.92%16.21%30.19%13.15%16.00%
Dividend
Annual Payout$1.56$3.40$0.77$1.80$2.60
Dividend Yield3.03%1.38%0.71%1.36%3.54%
Three-Year Dividend Growth-10.94%42.31%13.65%35.85%31.22%
Payout Ratio46.43%51.83%23.99%44.67%91.87%
Years of Consecutive Dividend Growth11 Years7 YearsN/A49 Years11 Years
Debt
Debt-to-Equity Ratio0.481.950.190.500.64
Current Ratio1.391.301.031.831.31
Quick Ratio1.181.020.821.421.07
Ownership Information
Institutional Ownership Percentage64.99%81.56%5.58%72.46%71.79%
Insider Ownership Percentage0.05%0.13%0.07%1.50%0.32%
Miscellaneous
Employees78,50035,00045,323109,00074,000
Shares Outstanding5.61 billion956.59 million2.35 billion1.77 billion2.53 billion
Next Earnings Date2/1/2022 (Estimated)2/4/2022 (Estimated)2/2/2022 (Estimated)1/26/2022 (Estimated)2/3/2022 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infectionMerck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
finance.yahoo.com - December 6 at 5:56 PM
Mercks (MRK) Keytruda Gets FDA Nod for Expanded Melanoma UseMerck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
msn.com - December 6 at 12:56 PM
Merck Supports Hiring Our Heroes Corporate Fellowship ProgramMerck Supports Hiring Our Heroes Corporate Fellowship Program
finance.yahoo.com - December 6 at 12:56 PM
Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19
finance.yahoo.com - December 6 at 12:56 PM
How millions of COVID vaccines are paid forHow millions of COVID vaccines are paid for
finance.yahoo.com - December 6 at 12:56 PM
UPDATE 1-Merck ties up with Thermo Fisher to make its COVID-19 pill in CanadaUPDATE 1-Merck ties up with Thermo Fisher to make its COVID-19 pill in Canada
finance.yahoo.com - December 6 at 12:56 PM
COVID: NYC expands vaccine mandate to include childrenCOVID: NYC expands vaccine mandate to include children
finance.yahoo.com - December 6 at 12:56 PM
Omicron variant: We don’t need to go into panic mode right now, physician saysOmicron variant: We don’t need to go into panic mode right now, physician says
finance.yahoo.com - December 6 at 12:56 PM
Heres Why Merck Lost Nearly $40 Billion in Value During NovemberHere's Why Merck Lost Nearly $40 Billion in Value During November
finance.yahoo.com - December 4 at 11:20 PM
Merck (NYSE:MRK) Is Paying Out A Larger Dividend Than Last YearMerck (NYSE:MRK) Is Paying Out A Larger Dividend Than Last Year
nasdaq.com - December 4 at 1:19 PM
Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To US$0.69Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To US$0.69
finance.yahoo.com - December 4 at 1:19 PM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete ResectionFDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
finance.yahoo.com - December 3 at 11:06 PM
Merck to supply up to 1 mln courses of COVID-19 pill to CanadaMerck to supply up to 1 mln courses of COVID-19 pill to Canada
finance.yahoo.com - December 3 at 6:05 PM
Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pillMerck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pill
finance.yahoo.com - December 3 at 6:05 PM
UPDATE 1-Merck to supply up to 1 mln courses of COVID-19 pill to CanadaUPDATE 1-Merck to supply up to 1 mln courses of COVID-19 pill to Canada
finance.yahoo.com - December 3 at 6:05 PM
Mercks Selloff Is an OverreactionMerck's Selloff Is an Overreaction
finance.yahoo.com - December 3 at 1:04 PM
Fighting for Health Equity From Inside the Health Care IndustryFighting for Health Equity From Inside the Health Care Industry
finance.yahoo.com - December 3 at 1:04 PM
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab PlanPharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
finance.yahoo.com - December 3 at 1:04 PM
COVID: ‘We need to stop wearing cloth masks and go to N95s for all,’ expert saysCOVID: ‘We need to stop wearing cloth masks and go to N95s for all,’ expert says
finance.yahoo.com - December 3 at 1:04 PM
FDA advisers recommend Merck’s COVID-19 pill in close voteFDA advisers recommend Merck’s COVID-19 pill in close vote
msn.com - December 2 at 8:27 PM
Belgium in talks to buy 10,000 doses of Mercks COVID-19 pill, health minister saysBelgium in talks to buy 10,000 doses of Merck's COVID-19 pill, health minister says
reuters.com - December 2 at 8:27 PM
Merck says its COVID-19 drug should be effective against any variantMerck says its COVID-19 drug should be effective against any variant
reuters.com - December 2 at 8:27 PM
Whats Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?What's Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?
nasdaq.com - December 2 at 8:27 PM
4 Dependable Healthcare Stocks to Buy Hand Over Fist Right Now4 Dependable Healthcare Stocks to Buy Hand Over Fist Right Now
stocknews.com - December 1 at 6:54 PM
Merck & Co. Inc. [MRK] Is Currently 0.03 below its 200 Period Moving Avg: What Does This Mean?Merck & Co. Inc. [MRK] Is Currently 0.03 below its 200 Period Moving Avg: What Does This Mean?
dbtnews.com - December 1 at 1:03 PM
FDA panel narrowly backs COVID-19 pill from MerckFDA panel narrowly backs COVID-19 pill from Merck
marketbeat.com - November 30 at 5:14 PM
Panel weighs safety, effectiveness of Mercks COVID-19 pillPanel weighs safety, effectiveness of Merck's COVID-19 pill
marketbeat.com - November 30 at 12:44 PM
Final US hurdle for Mercks COVID-19 pill: FDA panel reviewFinal US hurdle for Merck's COVID-19 pill: FDA panel review
marketbeat.com - November 30 at 9:14 AM
Merck & Co., Inc. (NYSE:MRK) Receives Buy Rating from SVB LeerinkMerck & Co., Inc. (NYSE:MRK) Receives Buy Rating from SVB Leerink
marketbeat.com - November 30 at 7:28 AM
Pfizer agrees to let other companies make its COVID-19 pillPfizer agrees to let other companies make its COVID-19 pill
marketbeat.com - November 16 at 7:05 AM
Johnson & Johnson to split into 2, aim for faster growthJohnson & Johnson to split into 2, aim for faster growth
marketbeat.com - November 12 at 11:42 AM
Johnson & Johnson to split into 2 companiesJohnson & Johnson to split into 2 companies
marketbeat.com - November 12 at 9:05 AM
3 COVID Stock Plays That Are Here to Stay (MRK)3 COVID Stock Plays That Are Here to Stay (MRK)
marketbeat.com - November 5 at 6:32 AM
Is it Time to Get into Merck Shares?Is it Time to Get into Merck Shares?
marketbeat.com - October 19 at 12:38 PM
The Top 3 Buy & Hold Healthcare Stocks for October (MRK)The Top 3 Buy & Hold Healthcare Stocks for October (MRK)
marketbeat.com - October 6 at 8:35 PM
Is American Airlines Stock Ready to Take Off?  (MRK)Is American Airlines Stock Ready to Take Off? (MRK)
marketbeat.com - October 3 at 10:50 PM
DateCompanyBrokerageAction
11/30/2021Merck & Co., Inc.SVB Leerink
Reiterated Rating
11/29/2021PfizerJPMorgan Chase & Co.
Boost Price Target
11/29/2021PfizerMorgan Stanley
Boost Price Target
11/29/2021Merck & Co., Inc.Morgan Stanley
Lower Price Target
11/29/2021Merck & Co., Inc.Citigroup
Downgrade
11/24/2021PfizerTruist Securities
Boost Price Target
11/24/2021PfizerTruist
Boost Price Target
11/24/2021Eli Lilly andTruist Securities
Boost Price Target
11/24/2021Eli Lilly andTruist
Boost Price Target
11/24/2021Merck & Co., Inc.Truist Securities
Boost Price Target
11/24/2021Merck & Co., Inc.Truist
Boost Price Target
11/18/2021PfizerBMO Capital Markets
Initiated Coverage
11/18/2021Eli Lilly andBMO Capital Markets
Initiated Coverage
11/18/2021Merck & Co., Inc.BMO Capital Markets
Initiated Coverage
11/17/2021PfizerBarclays
Set Price Target
11/11/2021PfizerIndependent Research
Upgrade
11/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
11/5/2021PfizerCantor Fitzgerald
Reiterated Rating
11/5/2021PfizerBenchmark
Boost Price Target
11/5/2021PfizerJPMorgan Chase & Co.
Set Price Target
11/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
11/4/2021Novo Nordisk A/SCredit Suisse Group
Reiterated Rating
11/4/2021Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/3/2021PfizerBarclays
Set Price Target
11/3/2021PfizerSVB Leerink
Lower Price Target
11/3/2021Novo Nordisk A/SBryan, Garnier & Co
Downgrade
11/2/2021Novo Nordisk A/SMorgan Stanley
Reiterated Rating
11/1/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
11/1/2021Merck & Co., Inc.Barclays
Boost Price Target
11/1/2021Merck & Co., Inc.Argus
Upgrade
10/29/2021Novo Nordisk A/SDNB Markets
Downgrade
10/29/2021Merck & Co., Inc.Morgan Stanley
Boost Price Target
10/28/2021Merck & Co., Inc.Mizuho
Initiated Coverage
10/27/2021Eli Lilly andMizuho
Lower Price Target
10/27/2021Abbott LaboratoriesAtlantic Securities
Upgrade
10/22/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
10/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
10/21/2021Abbott LaboratoriesSVB Leerink
Reiterated Rating
10/21/2021Abbott LaboratoriesRaymond James
Boost Price Target
10/18/2021Novo Nordisk A/SSEB Equities
Upgrade
10/14/2021Abbott LaboratoriesRedburn Partners
Initiated Coverage
10/12/2021PfizerMorgan Stanley
Boost Price Target
10/12/2021Merck & Co., Inc.Morgan Stanley
Boost Price Target
10/11/2021Eli Lilly andBerenberg Bank
Upgrade
10/10/2021Merck & Co., Inc.Berenberg Bank
Reiterated Rating
10/8/2021Abbott LaboratoriesCowen
Reiterated Rating
10/8/2021Merck & Co., Inc.Barclays
Boost Price Target
10/4/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
10/3/2021PfizerMizuho
Reiterated Rating
10/1/2021Abbott LaboratoriesCitigroup
Boost Price Target
10/1/2021Merck & Co., Inc.Mizuho
Initiated Coverage
9/29/2021Eli Lilly andCitigroup
Upgrade
9/24/2021Eli Lilly andJPMorgan Chase & Co.
Reiterated Rating
9/20/2021PfizerSVB Leerink
Boost Price Target
9/14/2021PfizerSVB Leerink
Reiterated Rating
9/13/2021PfizerJPMorgan Chase & Co.
Boost Price Target
9/7/2021Merck & Co., Inc.Morgan Stanley
Downgrade
9/3/2021Novo Nordisk A/SBerenberg Bank
Reiterated Rating
8/31/2021Abbott LaboratoriesBTIG Research
Boost Price Target
8/30/2021Eli Lilly andCowen
Boost Price Target
8/23/2021Novo Nordisk A/SCredit Suisse Group
Reiterated Rating
8/23/2021Novo Nordisk A/SCitigroup
Reiterated Rating
8/23/2021Abbott LaboratoriesCowen
Boost Price Target
8/17/2021Novo Nordisk A/SUBS Group
Reiterated Rating
8/11/2021Novo Nordisk A/SMorgan Stanley
Reiterated Rating
8/9/2021Eli Lilly andArgus
Boost Price Target
8/6/2021Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
8/5/2021Eli Lilly andDZ Bank
Upgrade
8/5/2021Novo Nordisk A/SBarclays
Reiterated Rating
8/5/2021Novo Nordisk A/SBank of America
Upgrade
8/5/2021Novo Nordisk A/SDNB Markets
Upgrade
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/3/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/30/2021PfizerMizuho
Boost Price Target
7/30/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/27/2021PfizerTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist Securities
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/9/2021Merck & Co., Inc.JPMorgan Chase & Co.
Lower Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Merck & Co., Inc.Truist Securities
Lower Price Target
6/3/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/20/2021Merck & Co., Inc.Argus
Reiterated Rating
4/30/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.